Therapeutic Response

pMMR status confers therapeutic sensitivity to Durvalumab in combination with Olaparib in patients with Endometrial Carcinoma.

Statements

Source and description

Lynparza (olaparib) [product information]. EMA. The European Medicines Agency (EMA) has authorized olaparib in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.